Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
ACVRL1 encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. Zusätzlich bieten wir Ihnen ACVRL1 Kits (32) und ACVRL1 Proteine (26) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 169 products:
Human Polyclonal ACVRL1 Primary Antibody für FACS, IHC (p) - ABIN392241
Strausberg, Feingold, Grouse, Derge, Klausner, Collins, Wagner, Shenmen, Schuler, Altschul, Zeeberg, Buetow, Schaefer, Bhat, Hopkins, Jordan, Moore, Max, Wang, Hsieh, Diatchenko, Marusina, Farmer et al.: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. ... in Proceedings of the National Academy of Sciences of the United States of America 2002
Show all 6 Pubmed References
Human Polyclonal ACVRL1 Primary Antibody für WB - ABIN1944774
Berg, Gallione, Stenzel, Johnson, Allen, Schwartz, Jackson, Porteous, Marchuk: The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. in American journal of human genetics 1997
Show all 3 Pubmed References
Human Polyclonal ACVRL1 Primary Antibody für IHC, IHC (p) - ABIN4279393
Cunha, Pardali, Thorikay, Anderberg, Hawinkels, Goumans, Seehra, Heldin, ten Dijke, Pietras: Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. in The Journal of experimental medicine 2010
Results show that ALK5 (zeige TGFBR1 Antikörper) and ALK1 play antagonistic roles in TGF-beta (zeige TGFB1 Antikörper)-induced podosome formation in aortic endothelial cells.
ALK1 and ALK5 (zeige TGFBR1 Antikörper) are both essential for correct regulation of VEGF (zeige VEGFA Antikörper), and that disruption of either pathway leads to disease.
alk1 loss has no effect on arterial endothelial cell proliferation but alters arterial endothelial cell migration within lumenized vessels.
Control of Notch (zeige NOTCH1 Antikörper) targets in arterial endothelium is context-dependent, with gene-specific and region-specific requirements for Notch (zeige NOTCH1 Antikörper) and Alk1
Blood flow is required not only for alk1 expression but also for Alk1 activity.
Study demonstrate that alk1 expression requires blood flow, and despite normal levels of shear stress, some flow-responsive genes are dysregulated in alk1 mutant arterial endothelial cells.
vbg encodes activin receptor-like kinase 1 (acvrl1), a TGFbeta (zeige TGFB1 Antikörper) type I receptor that is expressed predominantly in the endothelium of the vessels that become dilated in vbg mutants.
ENG (zeige ENG Antikörper) mutation carriers were more likely than ACVRL1 mutation carriers to have pAVMs (P < 0.001) or multiple lesions (P = 0.03), and to undergo procedural intervention (P = 0.02). The HHT severity score was significantly higher in ENG (zeige ENG Antikörper) than in ACVRL1 (P = 0.02).
These studies identified pathways mediating LDLR (zeige LDLR Antikörper)-independent uptake of LDL may provide unique opportunities to block the initiation of LDL accumulation in the vessel wall or augment hepatic LDLR (zeige LDLR Antikörper)-dependent clearance of LDL.
We have identified a novel role for ALK1 in cardiac remodeling
The present study showed that deletion-duplication mutations in the BMPR2 (zeige BMPR2 Antikörper) or ACVRL1 genes may not be associated with non-regression of Pulmonary arterial hypertension.
Study identified 2 non-synonymous missense mutations: c.C652T, p.R218W in ACVRL1, c.C717G, p.D239E in SGCD (zeige SGCD Antikörper) in Chinese population with total anomalous pulmonary venous return.
Mutations in ACVRL1 gene encoding for transforming growth factor (TGF)-[beta] superfamily have been identified in Pulmonary Arterial Hypertension.
Treatment-related telangiectasia was noted in 7% of patients, suggesting in vivo inhibition of the ALK-1 pathway.
Data indicate that simultaneous targeting of molecules that control distinct phases of angiogenesis, such as ALK1 and VEGFR (zeige KDR Antikörper), is a valid strategy for treatment of metastatic renal cell carcinoma (zeige MOK Antikörper) (mRCC).
Study showed that rs706819, rs2293094, and rs11169953 polymorphisms in the ACVRL1 gene are associated with higher susceptibility to brain arteriovenous malformations.
c.1027C > T(p.Gln343) mutation within the ACVRL1 gene in family with hereditary hemorrhagic telangiectasia
our data show that in a tumor environment BMP9 (zeige GDF2 Antikörper) and BMP10 (zeige BMP10 Antikörper) play different roles and thus blocking their shared receptor ALK1 is maybe not appropriate. Indeed, BMP9 (zeige GDF2 Antikörper), but not BMP10 (zeige BMP10 Antikörper), acts as a quiescence factor on tumor growth, lung metastasis and vessel normalization.
Data show that concomitant activin receptor-like kinase 1 (Acvrl1) and endoglin (Eng (zeige ENG Antikörper)) deficiency synergistically decreases pancreatic neuroendocrine tumor volume.
Global deletion of AlK-1 is associated with the development of high output heart failure without maladaptive remodeling.
These data indicate that both Itgb8 and Alk1 are important in maintaining normal cerebral angiogenesis in response to VEGF (zeige VEGFA Antikörper). Itgb8 deficiency enhances the formation of dysplastic vessels and hemorrhage in Alk1 (+/-) mice.
these studies characterize an accessory TGF-beta (zeige TGFB1 Antikörper)-stimulated BMP R-Smad (zeige SMAD1 Antikörper) signaling mechanism in interstitial cells of the developing lung.
this study demonstrates that ACVRL1 signaling plays a pivotal role whereby it suppresses plasmacytoid dendritic cell development while enhancing that of CD8alpha(+) dendritic cells, thus contributing to DC diversity development.
CD109 (zeige CD109 Antikörper) differentially regulates TGF-beta (zeige TGFB1 Antikörper)-induced ALK1-Smad1 (zeige SMAD1 Antikörper)/5 versus ALK5 (zeige TGFBR1 Antikörper)-Smad2 (zeige SMAD2 Antikörper)/3 pathways, leading to decreased extracellular matrix production in the skin; epidermal CD109 (zeige CD109 Antikörper) expression regulates dermal function through a paracrine mechanism
he results of the present study demonstrated that BMP9 promoted the osteoclast differentiation of osteoclast precursors via binding to the ALK1 receptor on the cell surface, and inhibiting the ERK1/2 signaling pathways in the cell
This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hemorrhagic telangiectasia type 2, also known as Rendu-Osler-Weber syndrome 2.
activin A receptor type II-like 1
, serine/threonine-protein kinase receptor R3
, serine/threonine-protein kinase receptor R3-like
, activin receptor-like kinase 1
, violet beauregarde
, TGF-B superfamily receptor type I
, activin A receptor, type II-like kinase 1
, Activin receptor like kinase 1
, activin receptor-like kinase-1